Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
Identifieur interne : 001362 ( Istex/Corpus ); précédent : 001361; suivant : 001363Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
Auteurs : Norio Nonomura ; Kazuo Nishimura ; Natsuki Takaha ; Hitoshi Inoue ; Takeshi Nomoto ; Youichi Mizutani ; Masahiro Nakao ; Akihiko Okuyama ; Tsuneharu MikiSource :
- International Journal of Urology [ 0919-8172 ] ; 2002-10.
English descriptors
- Teeft :
- Antegrade ejaculation, Bhcg, Cancer control, Chemotherapy, Cisplatinum, Dissection, Early stage testicular germ cell tumors, Ejaculation, Ejaculatory, Ejaculatory function, Etoposide, Iiib2, Immature teratoma, Liver metastases, Lumbar, Lumbar splanchnic nerves, Lymph, Metastatic, Metastatic testicular cancer, Node, Normal ejaculation, Postchemotherapy, Postchemotherapy rplnd, Primary chemotherapy, Recurrence, Residual, Retroperitoneal, Retroperitoneal lymph node dissection, Retroperitoneal lymphadenectomy, Retroperitoneal masses, Retroperitoneal recurrence, Rpln, Rplnd, Splanchnic, Superior hypogastric plexus, Teratoma, Testicular, Testicular cancer, Urol, Viable cancer cells.
Abstract
Background: Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.
Methods: Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve‐sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non‐seminoma. Three patients received high‐dose chemotherapy with carboplatin (250 mg/m2 per day × 5 days), etoposide (300 mg/m2 per day × 5 days) and ifosfamide (1.5 g/m2 per day × 5 days) in combination with peripheral blood stem cell transplantation.
Results: In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty‐two patients (84.6%) achieved antegrade ejaculation during a mean follow‐up at 3.9 months (range: 1–7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow‐up at 25.8 months (range: 6–76 months).
Conclusion: Nerve‐sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve‐sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor.
Url:
DOI: 10.1046/j.1442-2042.2002.00520.x
Links to Exploration step
ISTEX:4A9111F149B95F37F697EC6C89C0C5CF954A9B01Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title><author><name sortKey="Nonomura, Norio" sort="Nonomura, Norio" uniqKey="Nonomura N" first="Norio" last="Nonomura">Norio Nonomura</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: nono@uro.med.osaka‐u.ac.jp</mods:affiliation></affiliation></author><author><name sortKey="Nishimura, Kazuo" sort="Nishimura, Kazuo" uniqKey="Nishimura K" first="Kazuo" last="Nishimura">Kazuo Nishimura</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Takaha, Natsuki" sort="Takaha, Natsuki" uniqKey="Takaha N" first="Natsuki" last="Takaha">Natsuki Takaha</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Inoue, Hitoshi" sort="Inoue, Hitoshi" uniqKey="Inoue H" first="Hitoshi" last="Inoue">Hitoshi Inoue</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Nomoto, Takeshi" sort="Nomoto, Takeshi" uniqKey="Nomoto T" first="Takeshi" last="Nomoto">Takeshi Nomoto</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mizutani, Youichi" sort="Mizutani, Youichi" uniqKey="Mizutani Y" first="Youichi" last="Mizutani">Youichi Mizutani</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nakao, Masahiro" sort="Nakao, Masahiro" uniqKey="Nakao M" first="Masahiro" last="Nakao">Masahiro Nakao</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Okuyama, Akihiko" sort="Okuyama, Akihiko" uniqKey="Okuyama A" first="Akihiko" last="Okuyama">Akihiko Okuyama</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Miki, Tsuneharu" sort="Miki, Tsuneharu" uniqKey="Miki T" first="Tsuneharu" last="Miki">Tsuneharu Miki</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4A9111F149B95F37F697EC6C89C0C5CF954A9B01</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1046/j.1442-2042.2002.00520.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001362</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001362</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title><author><name sortKey="Nonomura, Norio" sort="Nonomura, Norio" uniqKey="Nonomura N" first="Norio" last="Nonomura">Norio Nonomura</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: nono@uro.med.osaka‐u.ac.jp</mods:affiliation></affiliation></author><author><name sortKey="Nishimura, Kazuo" sort="Nishimura, Kazuo" uniqKey="Nishimura K" first="Kazuo" last="Nishimura">Kazuo Nishimura</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Takaha, Natsuki" sort="Takaha, Natsuki" uniqKey="Takaha N" first="Natsuki" last="Takaha">Natsuki Takaha</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Inoue, Hitoshi" sort="Inoue, Hitoshi" uniqKey="Inoue H" first="Hitoshi" last="Inoue">Hitoshi Inoue</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Nomoto, Takeshi" sort="Nomoto, Takeshi" uniqKey="Nomoto T" first="Takeshi" last="Nomoto">Takeshi Nomoto</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mizutani, Youichi" sort="Mizutani, Youichi" uniqKey="Mizutani Y" first="Youichi" last="Mizutani">Youichi Mizutani</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Nakao, Masahiro" sort="Nakao, Masahiro" uniqKey="Nakao M" first="Masahiro" last="Nakao">Masahiro Nakao</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author><author><name sortKey="Okuyama, Akihiko" sort="Okuyama, Akihiko" uniqKey="Okuyama A" first="Akihiko" last="Okuyama">Akihiko Okuyama</name><affiliation><mods:affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</mods:affiliation></affiliation></author><author><name sortKey="Miki, Tsuneharu" sort="Miki, Tsuneharu" uniqKey="Miki T" first="Tsuneharu" last="Miki">Tsuneharu Miki</name><affiliation><mods:affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Urology</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF UROLOGY</title><idno type="ISSN">0919-8172</idno><idno type="eISSN">1442-2042</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="539">539</biblScope><biblScope unit="page" to="544">544</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2002-10">2002-10</date></imprint><idno type="ISSN">0919-8172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0919-8172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antegrade ejaculation</term><term>Bhcg</term><term>Cancer control</term><term>Chemotherapy</term><term>Cisplatinum</term><term>Dissection</term><term>Early stage testicular germ cell tumors</term><term>Ejaculation</term><term>Ejaculatory</term><term>Ejaculatory function</term><term>Etoposide</term><term>Iiib2</term><term>Immature teratoma</term><term>Liver metastases</term><term>Lumbar</term><term>Lumbar splanchnic nerves</term><term>Lymph</term><term>Metastatic</term><term>Metastatic testicular cancer</term><term>Node</term><term>Normal ejaculation</term><term>Postchemotherapy</term><term>Postchemotherapy rplnd</term><term>Primary chemotherapy</term><term>Recurrence</term><term>Residual</term><term>Retroperitoneal</term><term>Retroperitoneal lymph node dissection</term><term>Retroperitoneal lymphadenectomy</term><term>Retroperitoneal masses</term><term>Retroperitoneal recurrence</term><term>Rpln</term><term>Rplnd</term><term>Splanchnic</term><term>Superior hypogastric plexus</term><term>Teratoma</term><term>Testicular</term><term>Testicular cancer</term><term>Urol</term><term>Viable cancer cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.</div><div type="abstract">Methods: Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve‐sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non‐seminoma. Three patients received high‐dose chemotherapy with carboplatin (250 mg/m2 per day × 5 days), etoposide (300 mg/m2 per day × 5 days) and ifosfamide (1.5 g/m2 per day × 5 days) in combination with peripheral blood stem cell transplantation.</div><div type="abstract">Results: In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty‐two patients (84.6%) achieved antegrade ejaculation during a mean follow‐up at 3.9 months (range: 1–7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow‐up at 25.8 months (range: 6–76 months).</div><div type="abstract">Conclusion: Nerve‐sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve‐sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>rplnd</json:string><json:string>retroperitoneal</json:string><json:string>rpln</json:string><json:string>chemotherapy</json:string><json:string>node</json:string><json:string>ejaculation</json:string><json:string>bhcg</json:string><json:string>testicular</json:string><json:string>ejaculatory</json:string><json:string>urol</json:string><json:string>testicular cancer</json:string><json:string>teratoma</json:string><json:string>retroperitoneal lymph node dissection</json:string><json:string>postchemotherapy</json:string><json:string>splanchnic</json:string><json:string>ejaculatory function</json:string><json:string>etoposide</json:string><json:string>metastatic</json:string><json:string>iiib2</json:string><json:string>cisplatinum</json:string><json:string>lumbar splanchnic nerves</json:string><json:string>residual</json:string><json:string>postchemotherapy rplnd</json:string><json:string>retroperitoneal lymphadenectomy</json:string><json:string>recurrence</json:string><json:string>primary chemotherapy</json:string><json:string>superior hypogastric plexus</json:string><json:string>lymph</json:string><json:string>lumbar</json:string><json:string>retroperitoneal recurrence</json:string><json:string>normal ejaculation</json:string><json:string>liver metastases</json:string><json:string>cancer control</json:string><json:string>early stage testicular germ cell tumors</json:string><json:string>metastatic testicular cancer</json:string><json:string>immature teratoma</json:string><json:string>viable cancer cells</json:string><json:string>retroperitoneal masses</json:string><json:string>antegrade ejaculation</json:string><json:string>dissection</json:string></teeft></keywords><author><json:item><name>NORIO NONOMURA</name><affiliations><json:string>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</json:string><json:string>E-mail: nono@uro.med.osaka‐u.ac.jp</json:string></affiliations></json:item><json:item><name>KAZUO NISHIMURA</name><affiliations><json:string>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</json:string></affiliations></json:item><json:item><name>NATSUKI TAKAHA</name><affiliations><json:string>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</json:string></affiliations></json:item><json:item><name>HITOSHI INOUE</name><affiliations><json:string>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</json:string></affiliations></json:item><json:item><name>TAKESHI NOMOTO</name><affiliations><json:string>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</json:string></affiliations></json:item><json:item><name>YOUICHI MIZUTANI</name><affiliations><json:string>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</json:string></affiliations></json:item><json:item><name>MASAHIRO NAKAO</name><affiliations><json:string>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</json:string></affiliations></json:item><json:item><name>AKIHIKO OKUYAMA</name><affiliations><json:string>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</json:string></affiliations></json:item><json:item><name>TSUNEHARU MIKI</name><affiliations><json:string>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>chemotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>germ cell tumor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>nerve‐sparing retroperitoneal lymph node dissection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>testicular cancer</value></json:item></subject><articleId><json:string>IJU520</json:string></articleId><arkIstex>ark:/67375/WNG-TPW0X6G9-N</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background: Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.</abstract><qualityIndicators><score>5.19</score><pdfWordCount>2362</pdfWordCount><pdfCharCount>17181</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595 x 782.359 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>69</abstractWordCount><abstractCharCount>529</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title><pmid><json:string>12445231</json:string></pmid><genre><json:string>article</json:string></genre><host><title>International Journal of Urology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1442-2042</json:string></doi><issn><json:string>0919-8172</json:string></issn><eissn><json:string>1442-2042</json:string></eissn><publisherId><json:string>IJU</json:string></publisherId><volume>9</volume><issue>10</issue><pages><first>539</first><last>544</last><total>6</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-TPW0X6G9-N</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - urology & nephrology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - urology & nephrology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Urology</json:string></scopus></categories><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1046/j.1442-2042.2002.00520.x</json:string></doi><id>4A9111F149B95F37F697EC6C89C0C5CF954A9B01</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2002-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title><title level="a" type="short">Postchemotherapy nerve‐sparing RPLND</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">NORIO</forename><surname>NONOMURA</surname></persName><affiliation><orgName type="department">Department of Specific Organ Regulation (Urology)</orgName><orgName type="institution">Osaka University Graduate School of Medicine</orgName><address><addrLine>Suita and</addrLine></address></affiliation><affiliation>Norio Nonomura md phd, Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, 2‐2 Yamada‐oka, Suita 565‐0871, Japan. Email: nono@uro.med.osaka‐u.ac.jp</affiliation></author><author xml:id="author-0001"><persName><forename type="first">KAZUO</forename><surname>NISHIMURA</surname></persName><affiliation><orgName type="department">Department of Specific Organ Regulation (Urology)</orgName><orgName type="institution">Osaka University Graduate School of Medicine</orgName><address><addrLine>Suita and</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">NATSUKI</forename><surname>TAKAHA</surname></persName><affiliation><orgName type="department">Department of Specific Organ Regulation (Urology)</orgName><orgName type="institution">Osaka University Graduate School of Medicine</orgName><address><addrLine>Suita and</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">HITOSHI</forename><surname>INOUE</surname></persName><affiliation><orgName type="department">Department of Specific Organ Regulation (Urology)</orgName><orgName type="institution">Osaka University Graduate School of Medicine</orgName><address><addrLine>Suita and</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">TAKESHI</forename><surname>NOMOTO</surname></persName><affiliation><orgName type="department">Department of Urology</orgName><orgName type="institution">Kyoto Prefectural University of Medicine</orgName><address><addrLine>Kyoto</addrLine><country key="JP">JAPAN</country><country key="JP"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">YOUICHI</forename><surname>MIZUTANI</surname></persName><affiliation><orgName type="department">Department of Urology</orgName><orgName type="institution">Kyoto Prefectural University of Medicine</orgName><address><addrLine>Kyoto</addrLine><country key="JP">JAPAN</country><country key="JP"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">MASAHIRO</forename><surname>NAKAO</surname></persName><affiliation><orgName type="department">Department of Urology</orgName><orgName type="institution">Kyoto Prefectural University of Medicine</orgName><address><addrLine>Kyoto</addrLine><country key="JP">JAPAN</country><country key="JP"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first"> AKIHIKO</forename><surname>OKUYAMA</surname></persName><affiliation><orgName type="department">Department of Specific Organ Regulation (Urology)</orgName><orgName type="institution">Osaka University Graduate School of Medicine</orgName><address><addrLine>Suita and</addrLine></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">TSUNEHARU</forename><surname>MIKI</surname></persName><affiliation><orgName type="department">Department of Urology</orgName><orgName type="institution">Kyoto Prefectural University of Medicine</orgName><address><addrLine>Kyoto</addrLine><country key="JP">JAPAN</country><country key="JP"></country></address></affiliation></author><idno type="istex">4A9111F149B95F37F697EC6C89C0C5CF954A9B01</idno><idno type="ark">ark:/67375/WNG-TPW0X6G9-N</idno><idno type="DOI">10.1046/j.1442-2042.2002.00520.x</idno><idno type="unit">IJU520</idno><idno type="toTypesetVersion">file:IJU.IJU520.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Urology</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF UROLOGY</title><idno type="pISSN">0919-8172</idno><idno type="eISSN">1442-2042</idno><idno type="book-DOI">10.1111/(ISSN)1442-2042</idno><idno type="book-part-DOI">10.1111/iju.2002.9.issue-10</idno><idno type="product">IJU</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="539">539</biblScope><biblScope unit="page" to="544">544</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2002-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p><hi rend="italic">Background:</hi> Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.</p><p><hi rend="italic">Methods:</hi> Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve‐sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non‐seminoma. Three patients received high‐dose chemotherapy with carboplatin (250 mg/m<hi rend="superscript">2</hi> per day × 5 days), etoposide (300 mg/m<hi rend="superscript">2</hi> per day × 5 days) and ifosfamide (1.5 g/m<hi rend="superscript">2</hi> per day × 5 days) in combination with peripheral blood stem cell transplantation.</p><p><hi rend="italic">Results:</hi> In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty‐two patients (84.6%) achieved antegrade ejaculation during a mean follow‐up at 3.9 months (range: 1–7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow‐up at 25.8 months (range: 6–76 months).</p><p><hi rend="italic">Conclusion:</hi> Nerve‐sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve‐sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">chemotherapy</term><term xml:id="k2">germ cell tumor</term><term xml:id="k3">nerve‐sparing retroperitoneal lymph node dissection</term><term xml:id="k4">testicular cancer</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Pty</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1442-2042</doi><issn type="print">0919-8172</issn><issn type="electronic">1442-2042</issn><idGroup><id type="product" value="IJU"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNATIONAL JOURNAL OF UROLOGY">International Journal of Urology</title></titleGroup></publicationMeta><publicationMeta level="part" position="10010"><doi origin="wiley">10.1111/iju.2002.9.issue-10</doi><numberingGroup><numbering type="journalVolume" number="9">9</numbering><numbering type="journalIssue" number="10">10</numbering></numberingGroup><coverDate startDate="2002-10">October 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0053900" status="forIssue"><doi origin="wiley">10.1046/j.1442-2042.2002.00520.x</doi><idGroup><id type="unit" value="IJU520"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title></titleGroup><eventGroup><event type="firstOnline" date="2002-12-11"></event><event type="publishedOnlineFinalForm" date="2002-12-11"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="539">539</numbering><numbering type="pageLast" number="544">544</numbering></numberingGroup><correspondenceTo>Norio Nonomura <sc>md phd</sc>, Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, 2‐2 Yamada‐oka, Suita 565‐0871, Japan. Email: <email normalForm="nono@uro.med.osaka-u.ac.jp">nono@uro.med.osaka‐u.ac.jp</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IJU.IJU520.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 5 December 2001; accepted 8 April 2002.</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2612"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title><title type="shortAuthors">N Nonomura <i>et al.</i></title><title type="short">Postchemotherapy nerve‐sparing RPLND</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>NORIO</givenNames><familyName>NONOMURA</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>KAZUO</givenNames><familyName>NISHIMURA</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>NATSUKI</givenNames><familyName>TAKAHA</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>HITOSHI</givenNames><familyName>INOUE</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a2"><personName><givenNames>TAKESHI</givenNames><familyName>NOMOTO</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a2"><personName><givenNames>YOUICHI</givenNames><familyName>MIZUTANI</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a2"><personName><givenNames>MASAHIRO</givenNames><familyName>NAKAO</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1"><personName><givenNames> AKIHIKO</givenNames><familyName>OKUYAMA</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a2"><personName><givenNames>TSUNEHARU</givenNames><familyName>MIKI</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="JP"><unparsedAffiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">chemotherapy</keyword><keyword xml:id="k2">germ cell tumor</keyword><keyword xml:id="k3">nerve‐sparing retroperitoneal lymph node dissection</keyword><keyword xml:id="k4">testicular cancer</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p><b>Background:</b> Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.</p><p><b>Methods:</b> Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve‐sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non‐seminoma. Three patients received high‐dose chemotherapy with carboplatin (250 mg/m<sup>2</sup> per day × 5 days), etoposide (300 mg/m<sup>2</sup> per day × 5 days) and ifosfamide (1.5 g/m<sup>2</sup> per day × 5 days) in combination with peripheral blood stem cell transplantation.</p><p><b>Results:</b> In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty‐two patients (84.6%) achieved antegrade ejaculation during a mean follow‐up at 3.9 months (range: 1–7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow‐up at 25.8 months (range: 6–76 months).</p><p><b>Conclusion:</b> Nerve‐sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve‐sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Postchemotherapy nerve‐sparing RPLND</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy</title></titleInfo><name type="personal"><namePart type="given">NORIO</namePart><namePart type="family">NONOMURA</namePart><affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</affiliation><affiliation>E-mail: nono@uro.med.osaka‐u.ac.jp</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KAZUO</namePart><namePart type="family">NISHIMURA</namePart><affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NATSUKI</namePart><namePart type="family">TAKAHA</namePart><affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HITOSHI</namePart><namePart type="family">INOUE</namePart><affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TAKESHI</namePart><namePart type="family">NOMOTO</namePart><affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YOUICHI</namePart><namePart type="family">MIZUTANI</namePart><affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MASAHIRO</namePart><namePart type="family">NAKAO</namePart><affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AKIHIKO</namePart><namePart type="family">OKUYAMA</namePart><affiliation>Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine, Suita and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TSUNEHARU</namePart><namePart type="family">MIKI</namePart><affiliation>Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Pty</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2002-10</dateIssued><edition>Received 5 December 2001; accepted 8 April 2002.</edition><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">2</extent><extent unit="formulas">0</extent><extent unit="references">15</extent><extent unit="linksCrossRef">0</extent><extent unit="words">2612</extent></physicalDescription><abstract>Background: Nerve‐sparing techniques are commonly used in retroperitoneal lymph node dissection (RPLND) in patients with early stage testicular germ cell tumors to preserve postoperative ejaculation. The indications for nerve‐sparing procedures have been extended to patients who have residual retroperitoneal tumor postchemotherapy with an increase in the incidence of local recurrence. Here, we report on 26 Japanese men with advanced testicular cancer who underwent nerve‐sparing RPLND after partially successful chemotherapy.</abstract><abstract>Methods: Between January 1995 and December 2000, 26 patients with metastatic or recurrent testicular cancer underwent nerve‐sparing RPLND after chemotherapy. Eight patients had seminoma and 18 had non‐seminoma. Three patients received high‐dose chemotherapy with carboplatin (250 mg/m2 per day × 5 days), etoposide (300 mg/m2 per day × 5 days) and ifosfamide (1.5 g/m2 per day × 5 days) in combination with peripheral blood stem cell transplantation.</abstract><abstract>Results: In all cases, lumbar splanchnic nerves were preserved macroscopically during the operation, at least unilaterally. Twenty‐two patients (84.6%) achieved antegrade ejaculation during a mean follow‐up at 3.9 months (range: 1–7 months). Three patients have fathered children. Only one patient suffered a retroperitoneal recurrence during a median follow‐up at 25.8 months (range: 6–76 months).</abstract><abstract>Conclusion: Nerve‐sparing procedures for RPLND are appropriate for patients with metastatic testicular cancer, even after chemotherapy. The procedure preserves ejaculatory function in the majority of the patients without increasing the risk of local recurrence. Nerve‐sparing RPLND improves the quality of life in patients who require postchemotherapy RPLND to treat residual tumor.</abstract><subject lang="en"><genre>keywords</genre><topic>chemotherapy</topic><topic>germ cell tumor</topic><topic>nerve‐sparing retroperitoneal lymph node dissection</topic><topic>testicular cancer</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Urology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0919-8172</identifier><identifier type="eISSN">1442-2042</identifier><identifier type="DOI">10.1111/(ISSN)1442-2042</identifier><identifier type="PublisherID">IJU</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>539</start><end>544</end><total>6</total></extent></part></relatedItem><identifier type="istex">4A9111F149B95F37F697EC6C89C0C5CF954A9B01</identifier><identifier type="ark">ark:/67375/WNG-TPW0X6G9-N</identifier><identifier type="DOI">10.1046/j.1442-2042.2002.00520.x</identifier><identifier type="ArticleID">IJU520</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Blackwell Science Pty</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-TPW0X6G9-N/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Informatique/explor/SgmlV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001362 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001362 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Informatique
|area= SgmlV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4A9111F149B95F37F697EC6C89C0C5CF954A9B01
|texte= Nerve‐sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy
}}
| This area was generated with Dilib version V0.6.33. |  |